Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Pozo-Hernández C, Vargas-Castrillón E.

Lancet. 2009 Aug 29;374(9691):682; author reply 683. doi: 10.1016/S0140-6736(09)61552-X. No abstract available.

PMID:
19716955
2.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

3.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators.

Lancet. 2009 May 16;373(9676):1673-80. doi: 10.1016/S0140-6736(09)60734-0. Epub 2009 May 4.

PMID:
19411100
4.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Cao YB, Zhang JD, Shen H, Jiang YY.

Eur J Clin Pharmacol. 2010 Nov;66(11):1099-108. doi: 10.1007/s00228-010-0889-z. Epub 2010 Sep 2.

PMID:
20812009
5.
7.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

8.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Longo UG, Maffulli N, Denaro V.

Lancet. 2009 Aug 29;374(9691):681-2; author reply 683. doi: 10.1016/S0140-6736(09)61551-8. No abstract available.

PMID:
19716953
9.

Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

Nieto JA, Espada NG, Merino RG, González TC.

Thromb Res. 2012 Aug;130(2):183-91. doi: 10.1016/j.thromres.2012.02.011. Epub 2012 Mar 15.

PMID:
22425218
10.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Raju NC, Dimmitt S, Eikelboom JW.

Lancet. 2009 Aug 29;374(9691):681; author reply 683. doi: 10.1016/S0140-6736(09)61549-X. No abstract available.

PMID:
19716954
11.

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

Huisman MV, Quinlan DJ, Dahl OE, Schulman S.

Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.

12.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Stief T.

Lancet. 2009 Aug 29;374(9691):681; author reply 683. doi: 10.1016/S0140-6736(09)61550-6. No abstract available.

PMID:
19716952
13.

The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.

Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, Turpie AG.

J Bone Joint Surg Br. 2012 Nov;94(11):1573-8. doi: 10.1302/0301-620X.94B11.28955.

PMID:
23109641
14.

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; OdiXa-Knee Study Group.

J Thromb Haemost. 2005 Nov;3(11):2479-86.

15.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

16.

Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S.

Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.

PMID:
23197272
17.

A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.

Chahal GS, Saithna A, Brewster M, Gilbody J, Lever S, Khan WS, Foguet P.

Ortop Traumatol Rehabil. 2013 Mar-Apr;15(2):125-9. doi: 10.5604/15093492.1045953.

PMID:
23652532
18.

Rivaroxaban (Xarelto)--a new oral anticoagulant.

[No authors listed]

Med Lett Drugs Ther. 2011 Aug 22;53(1371):65-7. Review. No abstract available.

PMID:
21860366
19.

Rivaroxaban for thromboprophylaxis.

Lotke PA.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009675
20.

Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).

Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M.

Acta Anaesthesiol Scand. 2013 May;57(5):565-72. doi: 10.1111/aas.12069. Epub 2013 Jan 21.

PMID:
23336294

Supplemental Content

Support Center